Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 4/2010

01-12-2010 | NON-THEMATIC REVIEW

The guardians of the genome (p53, TA-p73, and TA-p63) are regulators of tumor suppressor miRNAs network

Author: Lakshmanane Boominathan

Published in: Cancer and Metastasis Reviews | Issue 4/2010

Login to get access

Abstract

The tumor suppressor p53 homologues, TA-p73, and p63 have been shown to function as tumor suppressors. However, how they function as tumor suppressors remains elusive. Here, I propose a number of tumor suppressor pathways that illustrate how the TA-p73 and p63 could function as negative regulators of invasion, metastasis, and cancer stem cells (CSCs) proliferation. Furthermore, I provide molecular insights into how TA-p73 and p63 could function as tumor suppressors. Remarkably, the guardians—p53, p73, and p63—of the genome are in control of most of the known tumor suppressor miRNAs, tumor suppressor genes, and metastasis suppressors by suppressing c-myc through miR-145/let-7/miR-34/TRIM32/PTEN/FBXW7. In particular, p53 and TA-p73/p63 appear to upregulate the expression of (1) tumor suppressor miRNAs, such as let-7, miR-34, miR-15/16a, miR-145, miR-29, miR-26, miR-30, and miR-146a; (2) tumor suppressor genes, such as PTEN, RBs, CDKN1a/b/c, and CDKN2a/b/c/d; (3) metastasis suppressors, such as Raf kinase inhibitory protein, CycG2, and DEC2, and thereby they enlarge their tumor suppressor network to inhibit tumorigenesis, invasion, angiogenesis, migration, metastasis, and CSCs proliferation.
Literature
1.
Boominathan, L. (2007). Some facts and thoughts: p73 as a tumor suppressor gene in the network of tumor suppressors. Molecular Cancer, 6, 27.PubMedCrossRef
2.
Chen, H. Z., Tsai, S. Y., & Leone, G. (2009). Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat Rev Cancer, 9(11), 785–97.PubMedCrossRef
3.
Puig, P., Capodieci, P., Drobnjak, M., Verbel, D., Prives, C., Cordon-Cardo, C., et al. (2003). p73 expression in human normal and tumor tissues: loss of p73alpha expression is associated with tumor progression in bladder cancer. Clinical Cancer Research, 9(15), 5642–5651.PubMed
4.
Urist, M. J., Di Como, C. J., Lu, M. L., Charytonowicz, E., Verbel, D., Crum, C. P., et al. (2002). Loss of p63 expression is associated with tumor progression in bladder cancer. The American Journal of Pathology, 161(4), 1199–1206.PubMed
5.
Park, B. J., Lee, S. J., Kim, J. I., Lee, S. J., Lee, C. H., Chang, S. G., et al. (2000). Frequent alteration of p63 expression in human primary bladder carcinomas. Cancer Research, 60(13), 3370–3374.PubMed
6.
Oya, M., & Schulz, W. A. (2000). Decreased expression of p57(KIP2)mRNA in human bladder cancer. British Journal of Cancer, 83(5), 626–631.PubMedCrossRef
7.
Kunze, E., Wendt, M., & Schlott, T. (2006). Promoter hypermethylation of the 14-3-3 sigma, SYK and CAGE-1 genes is related to the various phenotypes of urinary bladder carcinomas and associated with progression of transitional cell carcinomas. International Journal of Molecular Medicine, 18(4), 547–557.PubMed
8.
Moreira, J. M., Gromov, P., & Celis, J. E. (2004). Expression of the tumor suppressor protein 14-3-3 sigma is down-regulated in invasive transitional cell carcinomas of the urinary bladder undergoing epithelial-to-mesenchymal transition. Molecular & Cellular Proteomics, 3(4), 410–419.CrossRef
9.
Le Frère-Belda, M. A., Cappellen, D., Daher, A., Gil-Diez-de-Medina, S., Besse, F., Abbou, C. C., et al. (2001). p15(INK4b) in bladder carcinomas: decreased expression in superficial tumours. British Journal of Cancer, 85(10), 1515–1521.PubMedCrossRef
10.
Pymar, L. S., Platt, F. M., Askham, J. M., Morrison, E. E., & Knowles, M. A. (2008). Bladder tumour-derived somatic TSC1 missense mutations cause loss of function via distinct mechanisms. Human Molecular Genetics, 17(13), 2006–2017.PubMedCrossRef
11.
Vecchione, A., Ishii, H., Baldassarre, G., Bassi, P., Trapasso, F., Alder, H., et al. (2002). FEZ1/LZTS1 is down-regulated in high-grade bladder cancer, and its restoration suppresses tumorigenicity in transitional cell carcinoma cells. The American Journal of Pathology, 160(4), 1345–1352.PubMed
12.
Tsuruta, H., Kishimoto, H., Sasaki, T., Horie, Y., Natsui, M., Shibata, Y., et al. (2006). Hyperplasia and carcinomas in PTEN-deficient mice and reduced PTEN protein in human bladder cancer patients. Cancer Research, 66(17), 8389–8396.PubMedCrossRef
13.
Kim, E. J., Kim, Y. J., Jeong, P., Ha, Y. S., Bae, S. C., & Kim, W. J. (2008). Methylation of the RUNX3 promoter as a potential prognostic marker for bladder tumor. Urology, 180(3), 1141–1145.CrossRef
14.
Ostenfeld, M. S., Bramsen, J. B., Lamy, P., Villadsen, S. B., Fristrup, N., Sørensen, K. D., et al. (2010). miR-145 induces caspase-dependent and -independent cell death in urothelial cancer cell lines with targeting of an expression signature present in Ta bladder tumors. Oncogene, 29(7), 1073–1084.PubMedCrossRef
15.
Wiklund, E.D., Bramsen, J.B., Hulf, T., Dyrskjøt, L., Ramanathan, R., Hansen, T.B., et al. (2010). Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer. Int J Cancer (in press)
16.
Yu, F., Yao, H., Zhu, P., Zhang, X., Pan, Q., Gong, C., et al. (2007). let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell, 131(6), 1109–1123.PubMedCrossRef
17.
Mo, L., Zheng, X., Huang, H. Y., Shapiro, E., Lepor, H., Cordon-Cardo, C., et al. (2007). Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis. The Journal of Clinical Investigation, 117(2), 314–325.PubMedCrossRef
18.
Knowles, M. A., Platt, F. M., Ross, R. L., & Hurst, C. D. (2009). Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer. Cancer and Metastasis Reviews, 28(3–4), 305–316. Review.PubMedCrossRef
19.
Tomasini, R., Tsuchihara, K., Wilhelm, M., Fujitani, M., Rufini, A., Cheung, C. C., et al. (2008). TAp73 knockout shows genomic instability with infertility and tumor suppressor functions. Genes & Development, 22(19), 2677–2691.CrossRef
20.
He, L., Fan, C., Ning, X., Feng, X., Liu, Y., Chen, B., et al. (2008). Interaction of p14ARF with Brca1 in cancer cell lines and primary breast cancer. Cell Biology International, 32(10), 1302–1309.PubMedCrossRef
21.
Zhu, J. W., Field, S. J., Gore, L., Thompson, M., Yang, H., Fujiwara, Y., et al. (2001). E2F1 and E2F2 determine thresholds for antigen-induced T-cell proliferation and suppress tumorigenesis. Molecular and Cellular Biology, 2001(24), 8547–8564.CrossRef
22.
Opavsky, R., Tsai, S. Y., Guimond, M., Arora, A., Opavska, J., Becknell, B., et al. (2007). Specific tumor suppressor function for E2F2 in Myc-induced T cell lymphomagenesis. Proceedings of the National Academy of Sciences of the United States of America, 104(39), 15400–15405.PubMedCrossRef
23.
Friedman, L. S., Thistlethwaite, F. C., Patel, K. J., Yu, V. P., Lee, H., Venkitaraman, A. R., et al. (1998). Thymic lymphomas in mice with a truncating mutation in Brca2. Cancer Research, 58(7), 1338–1343.PubMed
24.
Szremska, A. P., Kenner, L., Weisz, E., Ott, R. G., Passegué, E., Artwohl, M., et al. (2003). JunB inhibits proliferation and transformation in B-lymphoid cells. Blood, 102(12), 4159–4165.PubMedCrossRef
25.
Passegué, E., & Wagner, E. F. (2000). JunB suppresses cell proliferation by transcriptional activation of p16(INK4a) expression. The EMBO Journal, 19(12), 2969–2979.PubMedCrossRef
26.
Passegué, E., Jochum, W., Schorpp-Kistner, M., Möhle-Steinlein, U., & Wagner, E. F. (2001). Chronic myeloid leukemia with increased granulocyte progenitors in mice lacking JunB expression in the myeloid lineage. Cell, 104(1), 21–32.PubMedCrossRef
27.
Passegué, E., Wagner, E. F., & Weissman, I. L. (2004). JunB deficiency leads to a myeloproliferative disorder arising from hematopoietic stem cells. Cell, 119(3), 431–443.PubMedCrossRef
28.
Corn, P. G., Kuerbitz, S. J., van Noesel, M. M., Esteller, M., Compitello, N., Baylin, S. B., et al. (1999). Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt’s lymphoma is associated with 5′ CpG island methylation. Cancer Research, 59(14), 3352–3356.PubMed
29.
Yamaguchi, H., Inokuchi, K., Sakuma, Y., & Dan, K. (2001). Mutation of the p51/p63 gene is associated with blastic crisis in chronic myelogenous leukemia. Leukemia, 11, 1729–1734.
30.
Marreiros, A., Dudgeon, K., Dao, V., Grimm, M. O., Czolij, R., Crossley, M., et al. (2005). KAI1 promoter activity is dependent on p53, junB and AP2: evidence for a possible mechanism underlying loss of KAI1 expression in cancer cells. Oncogene, 24(4), 637–649.PubMedCrossRef
31.
Koster, M. I., Kim, S., Huang, J., Williams, T., & Roop, D. R. (2006). TAp63alpha induces AP-2gamma as an early event in epidermal morphogenesis. Developmental Biology, 289(1), 253–261.PubMedCrossRef
32.
Li, H., Watts, G. S., Oshiro, M. M., Futscher, B. W., & Domann, F. E. (2006). AP-2alpha and AP-2gamma are transcriptional targets of p53 in human breast carcinoma cells. Oncogene, 25(39), 5405–5415.PubMedCrossRef
33.
Mitchell, D. C., Abdelrahim, M., Weng, J., Stafford, L. J., Safe, S., Bar-Eli, M., et al. (2006). Regulation of KiSS-1 metastasis suppressor gene expression in breast cancer cells by direct interaction of transcription factors activator protein-2alpha and specificity protein-1. The Journal of Biological Chemistry, 281(1), 51–58.PubMedCrossRef
34.
Sanchez-Carbayo, M., Capodieci, P., & Cordon-Cardo, C. (2003). Tumor suppressor role of KiSS-1 in bladder cancer: loss of KiSS-1 expression is associated with bladder cancer progression and clinical outcome. The American Journal of Pathology, 162(2), 609–617.PubMed
35.
Dews, M., Homayouni, A., Yu, D., Murphy, D., Sevignani, C., Wentzel, E., et al. (2006). Augmentation of tumor angiogenesis by a Myc-activated miRNA cluster. Nature Genetics, 38(9), 1060–1065.PubMedCrossRef
36.
Wang, S. P., Wang, W. L., Chang, Y. L., Wu, C. T., Chao, Y. C., Kao, S. H., et al. (2009). p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug. Nature Cell Biology, 6, 694–704.CrossRef
37.
Lim, S. O., Kim, H., & Jung, G. (2010). p53 inhibits tumor cell invasion via the degradation of snail protein in hepatocellular carcinoma. FEBS Letters, 584(11), 2231–2236.PubMedCrossRef
38.
Kudo-Saito, C., Shirako, H., Takeuchi, T., & Kawakami, Y. (2009). Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. Cancer Cell, 15(3), 195–206.PubMedCrossRef
39.
Beach, S., Tang, H., Park, S., Dhillon, A. S., Keller, E. T., Kolch, W., et al. (2008). Snail is a repressor of RKIP transcription in metastatic prostate cancer cells. Oncogene, 27(15), 2243–2248.PubMedCrossRef
40.
Jin, H., Yu, Y., Zhang, T., Zhou, X., Zhou, J., Jia, L., et al. (2010). Snail is critical for tumor growth and metastasis of ovarian carcinoma. International Journal of Cancer, 126(9), 2102–2111.
41.
Dangi-Garimella, S., Yun, J., Eves, E. M., Newman, M., Erkeland, S. J., Hammond, S. M., et al. (2009). Raf kinase inhibitory protein suppresses a metastasis signalling cascade involving LIN28 and let-7. The EMBO Journal, 28(4), 347–358.PubMedCrossRef
42.
Ries, S., Biederer, C., Woods, D., Shifman, O., Shirasawa, S., Sasazuki, T., et al. (2000). Opposing effects of Ras on p53: transcriptional activation of mdm2 and induction of p19ARF. Cell, 103(2), 321–330.PubMedCrossRef
43.
Ozaki, T., Okoshi, R., Sang, M., Kubo, N., & Nakagawara, A. (2009). Acetylation status of E2F-1 has an important role in the regulation of E2F-1-mediated transactivation of tumor suppressor p73. Biochemical and Biophysical Research Communications, 386(1), 207–211.PubMedCrossRef
44.
Sayan, B. S., Sayan, A. E., Yang, A. L., Aqeilan, R. I., Candi, E., Cohen, G. M., et al. (2007). Cleavage of the transactivation-inhibitory domain of p63 by caspases enhances apoptosis. Proceedings of the National Academy of Sciences of the United States of America, 104(26), 10871–10876.PubMedCrossRef
45.
Li, N., Fu, H., Tie, Y., Hu, Z., Kong, W., Wu, Y., et al. (2009). miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. Cancer Letters, 275(1), 44–53.PubMedCrossRef
46.
Salvi, A., Sabelli, C., Moncini, S., Venturin, M., Arici, B., Riva, P., et al. (2009). MicroRNA-23b mediates urokinase and c-met downmodulation and a decreased migration of human hepatocellular carcinoma cells. The FEBS Journal, 276(11), 2966–2982.PubMedCrossRef
47.
Yamakuchi, M., Lotterman, C. D., Bao, C., Hruban, R. H., Karim, B., Mendell, J. T., et al. (2010). p53- induced microRNA-107 inhibits HIF-1 and tumor angiogenesis. Proceedings of the National Academy of Sciences of the United States of America, 107(14), 6334–6339.PubMedCrossRef
48.
Sachdeva, M., & Mo, Y. Y. (2010). MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1. Cancer Research, 70(1), 378–387.PubMedCrossRef
49.
Chen, X., Gong, J., Zeng, H., Chen, N., Huang, R., et al. (2010). MicroRNA145 targets BNIP3 and suppresses prostate cancer progression. Cancer Research, 70(7), 2728–2738.PubMedCrossRef
50.
Chiyomaru, T., Enokida, H., Tatarano, S., Kawahara, K., Uchida, Y., Nishiyama, K., et al. (2010). miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer. British Journal of Cancer, 102(5), 883–891.PubMedCrossRef
51.
Kano, M., Seki, N., Kikkawa, N., Fujimura, L., Hoshino, I., Akutsu, Y., Chiyomaru, T., Enokida, H., Nakagawa, M., Matsubara, H. (2010). miR-145, miR-133a and miR-133b: Tumor suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int J Cancer (in press)
52.
Barbieri, C. E., Tang, L. J., Brown, K. A., & Pietenpol, J. A. (2006). Loss of p63 leads to increased cell migration and up-regulation of genes involved in invasion and metastasis. Cancer Research, 66(15), 7589–7597.PubMedCrossRef
53.
54.
55.
Leong, K. G., Niessen, K., Kulic, I., Raouf, A., Eaves, C., Pollet, I., et al. (2007). Jagged1-mediated Notch activation induces epithelial-to-mesenchymal transition through Slug-induced repression of E-cadherin. The Journal of Experimental Medicine, 204(12), 2935–2948.PubMedCrossRef
56.
Hooper, C., Tavassoli, M., Chapple, J. P., Uwanogho, D., Goodyear, R., Melino, G., et al. (2006). TAp73 isoforms antagonize Notch signalling in SH-SY5Y neuroblastomas and in primary neurones. Journal of Neurochemistry, 99(3), 989–999.PubMedCrossRef
57.
Chu, W. K., Dai, P. M., Li, H. L., & Chen, J. K. (2008). Transcriptional activity of the DeltaNp63 promoter is regulated by STAT3. The Journal of Biological Chemistry, 283(12), 7328–7337.PubMedCrossRef
58.
Nishi, H., Senoo, M., Nishi, K. H., Murphy, B., Rikiyama, T., Matsumura, Y., et al. (2001). p53 Homologue p63 represses epidermal growth factor receptor expression. The Journal of Biological Chemistry, 276(45), 41717–41724.PubMedCrossRef
59.
Lo, H. W., Hsu, S. C., Xia, W., Cao, X., Shih, J. Y., Wei, Y., et al. (2007). Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial–mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. Cancer Research, 67(19), 9066–9076.PubMedCrossRef
60.
Cho, M. S., Chan, I. L., & Flores, E. R. (2010). DeltaNp63 transcriptionally regulates brachyury, a gene with diverse roles in limb development, tumorigenesis and metastasis. Cell Cycle, 9(12).
61.
Fernando, R. I., Litzinger, M., Trono, P., Hamilton, D. H., Schlom, J., & Palena, C. (2010). The T-box transcription factor Brachyury promotes epithelial-mesenchymal transition in human tumor cells. The Journal of Clinical Investigation, 120(2), 533–544.PubMedCrossRef
62.
Senoo, M., Matsumura, Y., & Habu, S. (2002). TAp63gamma (p51A) and dNp63alpha (p73L), two major isoforms of the p63 gene, exert opposite effects on the vascular endothelial growth factor (VEGF) gene expression. Oncogene, 21(16), 2455–2465.PubMedCrossRef
63.
Yang, A. D., Camp, E. R., Fan, F., Shen, L., Gray, M. J., Liu, W., et al. (2006). Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in human pancreatic carcinoma cells. Cancer Research, 66(1), 46–51.PubMedCrossRef
64.
Mak, P., Leav, I., Pursell, B., Bae, D., Yang, X., Taglienti, C. A., et al. (2010). ERbeta impedes prostate cancer EMT by destabilizing HIF-1alpha and inhibiting VEGF-mediated snail nuclear localization: implications for Gleason grading. Cancer Cell, 17(4), 319–332.PubMedCrossRef
65.
Yang, M. H., Wu, M. Z., Chiou, S. H., Chen, P. M., Chang, S. Y., Liu, C. J., et al. (2008). Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nature Cell Biology, 10(3), 295–305.PubMedCrossRef
66.
Ansieau, S., Bastid, J., Doreau, A., Morel, A. P., Bouchet, B. P., Thomas, C., et al. (2008). Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence. Cancer Cell, 14(1), 79–89.PubMedCrossRef
67.
Zhou, B. P., Deng, J., Xia, W., Xu, J., Li, Y. M., Gunduz, M., et al. (2004). Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial–mesenchymal transition. Nature Cell Biology, 6(10), 931–940.PubMedCrossRef
68.
Fukushima, H., Koga, F., Kawakami, S., Fujii, Y., Yoshida, S., Ratovitski, E., et al. (2009). Loss of DeltaNp63alpha promotes invasion of urothelial carcinomas via N-cadherin/Src homology and collagen/extracellular signal-regulated kinase pathway. Cancer Research, 69(24), 9263–9270.PubMedCrossRef
69.
Shin, S., Dimitri, C. A., Yoon, S. O., Dowdle, W., & Blenis, J. (2010). ERK2 but not ERK1 induces epithelial-to-mesenchymal transformation via DEF motif-dependent signaling events. Molecular Cell, 38(1), 114–127.PubMedCrossRef
70.
Higashikawa, K., Yoneda, S., Tobiume, K., Saitoh, M., Taki, M., et al. (2009). DeltaNp63alpha-dependent expression of Id-3 distinctively suppresses the invasiveness of human squamous cell carcinoma. International Journal of Cancer, 124(12), 2837–2844.CrossRef
71.
Kommagani, R., Leonard, M. K., Lewis, S., Romano, R. A., Sinha, S., & Kadakia, M. P. (2009). Regulation of VDR by deltaNp63alpha is associated with inhibition of cell invasion. Journal of Cell Science, 122(Pt 16), 2828–2835.PubMedCrossRef
72.
Kommagani, R., Payal, V., & Kadakia, M. P. (2007). Differential regulation of vitamin D receptor (VDR) by the p53 Family: p73-dependent induction of VDR upon DNA damage. The Journal of Biological Chemistry, 282(41), 29847–29854.PubMedCrossRef
73.
Pálmer, H. G., González-Sancho, J. M., Espada, J., Berciano, M. T., Puig, I., Baulida, J., et al. (2001). Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. The Journal of Cell Biology, 154(2), 369–387.PubMedCrossRef
74.
Pálmer, H. G., Larriba, M. J., García, J. M., Ordóñez-Morán, P., Peña, C., Peiró, S., et al. (2004). The transcription factor SNAIL represses vitamin D receptor expression and responsiveness in human colon cancer. Natural Medicines, 10(9), 917–919.CrossRef
75.
Peña, C., García, J. M., Silva, J., García, V., Rodríguez, R., Alonso, I., et al. (2005). E-cadherin and vitamin D receptor regulation by SNAIL and ZEB1 in colon cancer: clinicopathological correlations. Human Molecular Genetics, 14(22), 3361–3370.PubMedCrossRef
76.
Higashikawa, K., Yoneda, S., Tobiume, K., Taki, M., & Shigeishi, H. (2007). Snail-induced down-regulation of DeltaNp63alpha acquires invasive phenotype of human squamous cell carcinoma. Cancer Research, 67(19), 9207–9213.PubMedCrossRef
77.
Aberdam, D., Gambaro, K., Rostagno, P., Aberdam, E., de la Forest Divonne, S., & Rouleau, M. (2007). Key role of p63 in BMP-4-induced epidermal commitment of embryonic stem cells. Cell Cycle, 6(3), 291–294.PubMed
78.
Chikh, A., Sayan, E., Thibaut, S., Lena, A. M., DiGiorgi, S., Bernard, B. A., et al. (2007). Expression of GATA-3 in epidermis and hair follicle: relationship to p63. Biochemical and Biophysical Research Communications, 361(1), 1–6.PubMedCrossRef
79.
Yan, W., Cao, Q. J., Arenas, R. B., Bentley, B., & Shao, R. (2010). GATA3 inhibits breast cancer metastasis through the reversal of epithelial–mesenchymal transition. The Journal of Biological Chemistry, 285(18), 14042–14051.PubMedCrossRef
80.
Kouros-Mehr, H., Bechis, S. K., Slorach, E. M., Littlepage, L. E., Egeblad, M., Ewald, A. J., et al. (2008). GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model. Cancer Cell, 13(2), 141–152.PubMedCrossRef
81.
Dydensborg, A. B., Rose, A. A., Wilson, B. J., Grote, D., Paquet, M., Giguère, V., et al. (2009). GATA3 inhibits breast cancer growth and pulmonary breast cancer metastasis. Oncogene, 28(29), 2634–2642.PubMedCrossRef
82.
Candi, E., Terrinoni, A., Rufini, A., Chikh, A., Lena, A. M., Suzuki, Y., et al. (2006). p63 is upstream of IKK alpha in epidermal development. Journal of Cell Science, 119(Pt 22), 4617–4622.PubMedCrossRef
83.
Descargues, P., Sil, A. K., & Karin, M. (2008). IKKalpha, a critical regulator of epidermal differentiation and a suppressor of skin cancer. The EMBO Journal, 27(20), 2639–2647.PubMedCrossRef
84.
Marinari, B., Ballaro, C., Koster, M. I., Giustizieri, M. L., Moretti, F., Crosti, F., et al. (2009). IKKalpha is a p63 transcriptional target involved in the pathogenesis of ectodermal dysplasias. The Journal of Investigative Dermatology, 129(1), 60–69.PubMedCrossRef
85.
Koster, M. I., Dai, D., Marinari, B., Sano, Y., Costanzo, A., Karin, M., et al. (2007). p63 induces key target genes required for epidermal morphogenesis. Proceedings of the National Academy of Sciences of the United States of America, 104(9), 3255–3260.PubMedCrossRef
86.
Beretta, C., Chiarelli, A., Testoni, B., Mantovani, R., & Guerrini, L. (2005). Regulation of the cyclin-dependent kinase inhibitor p57Kip2 expression by p63. Cell Cycle, 11, 1625–1631.
87.
Carroll, D. K., Carroll, J. S., Leong, C. O., Cheng, F., Brown, M., Mills, A. A., et al. (2006). p63 regulates an adhesion programme and cell survival in epithelial cells. Nature Cell Biology, 6, 551–561.CrossRef
88.
Sato, K., Tomizawa, Y., Iijima, H., Saito, R., Ishizuka, T., Nakajima, T., et al. (2006). Epigenetic inactivation of the RUNX3 gene in lung cancer. Oncology Reports, 15(1), 129–135.PubMed
89.
Zamisch, M., Tian, L., Grenningloh, R., Xiong, Y., Wildt, K. F., Ehlers, M., et al. (2009). The transcription factor Ets1 is important for CD4 repression and Runx3 up-regulation during CD8 T cell differentiation in the thymus. The Journal of Experimental Medicine, 206(12), 2685–2699.PubMedCrossRef
90.
Lee, K. S., Lee, Y. S., Lee, J. M., Ito, K., Cinghu, S., Kim, J. H., et al. (2010). Runx3 is required for the differentiation of lung epithelial cells and suppression of lung cancer. Oncogene, 29(23), 3349–3361.PubMedCrossRef
91.
Chang, T. L., Ito, K., Ko, T. K., Liu, Q., Salto-Tellez, M., Yeoh, K. G., et al. (2010). Claudin-1 has tumor suppressive activity and is a direct target of RUNX3 in gastric epithelial cells. Gastroenterology, 138(1), 255–265. e1–3.PubMedCrossRef
92.
Lopardo, T., Lo Iacono, N., Marinari, B., Giustizieri, M. L., Cyr, D. G., Merlo, G., et al. (2008). Claudin-1 is a p63 target gene with a crucial role in epithelial development. PLoS ONE, 3(7), e2715.PubMedCrossRef
93.
Chao, Y. C., Pan, S. H., Yang, S. C., Yu, S. L., Che, T. F., Lin, C. W., et al. (2009). Claudin-1 is a metastasis suppressor and correlates with clinical outcome in lung adenocarcinoma. American Journal of Respiratory and Critical Care Medicine, 179(2), 123–133.PubMedCrossRef
94.
Berger, A. H., Niki, M., Morotti, A., Taylor, B. S., Socci, N. D., Viale, A., et al. (2010). Identification of DOK genes as lung tumor suppressors. Nature Genetics, 42(3), 216–223.PubMedCrossRef
95.
Niki, M., Di Cristofano, A., Zhao, M., Honda, H., Hirai, H., Van Aelst, L., et al. (2004). Role of Dok-1 and Dok-2 in leukemia suppression. The Journal of Experimental Medicine, 200(12), 1689–1695.PubMedCrossRef
96.
Wu, G., Nomoto, S., Hoque, M. O., Dracheva, T., Osada, M., Lee, C. C., et al. (2003). DeltaNp63alpha and TAp63alpha regulate transcription of genes with distinct biological functions in cancer and development. Cancer Research, 63(10), 2351–2357.PubMed
97.
Zamò, A., Malpeli, G., Scarpa, A., Doglioni, C., Chilosi, M., & Menestrina, F. (2005). Expression of TP73L is a helpful diagnostic marker of primary mediastinal large B-cell lymphomas. Modern Pathology, 18(11), 1448–1453.PubMedCrossRef
98.
Pruneri, G., Fabris, S., Dell’Orto, P., Biasi, M. O., Valentini, S., Del Curto, B., et al. (2005). The transactivating isoforms of p63 are overexpressed in high-grade follicular lymphomas independent of the occurrence of p63 gene amplification. The Journal of Pathology, 206(3), 337–345.PubMedCrossRef
99.
Nicolas, M., Koster, M. I., Lu, S. L., White, L. D., Wang, X. J., & Roop, D. R. (2006). Reactivation of developmentally expressed p63 isoforms predisposes to tumor development and progression. Cancer Research, 66(8), 3981–3986.CrossRef
100.
Sasaki, Y., Ishida, S., Morimoto, I., Yamashita, T., Kojima, T., Kihara, C., et al. (2002). The p53 family member genes are involved in the Notch signal pathway. The Journal of Biological Chemistry, 277(1), 719–724.PubMedCrossRef
101.
Shimomura, Y., Wajid, M., Shapiro, L., & Christiano, A. M. (2008). P-cadherin is a p63 target gene with a crucial role in the developing human limb bud and hair follicle. Development, 135(4), 743–753.PubMedCrossRef
102.
Taniuchi, K., Nakagawa, H., Hosokawa, M., Nakamura, T., Eguchi, H., Ohigashi, H., et al. (2005). Overexpressed P-cadherin/CDH3 promotes motility of pancreatic cancer cells by interacting with p120ctn and activating rho-family GTPases. Cancer Research, 65(8), 3092–3099.PubMed
103.
Bui, T., Sequeira, J., Wen, T. C., Sola, A., Higashi, Y., Kondoh, H., et al. (2009). ZEB1 links p63 and p73 in a novel neuronal survival pathway rapidly induced in response to cortical ischemia. PLoS ONE, 4(2), e4373. PLoS One. 4(8):e6816.PubMedCrossRef
104.
Nicolas, M., Wolfer, A., Raj, K., Kummer, J. A., Mill, P., van Noort, M., et al. (2003). Notch1 functions as a tumor suppressor in mouse skin. Nature Genetics, 33(3), 416–421.PubMedCrossRef
105.
Weng, A. P., Ferrando, A. A., Lee, W., Morris, J. P., 4th, Silverman, L. B., Sanchez-Irizarry, C., et al. (2004). Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science, 306(5694), 269–271.PubMedCrossRef
106.
Lefort, K., Mandinova, A., Ostano, P., Kolev, V., Calpini, V., Kolfschoten, I., et al. (2007). Notch1 is a p53 target gene involved in human keratinocyte tumor suppression through negative regulation of ROCK1/2 and MRCKalpha kinases. Genes & Development, 21(5), 562–577.CrossRef
107.
Ji, Q., Hao, X., Zhang, M., Tang, W., Yang, M., Li, L., et al. (2009). MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS ONE, 4(8), e6816.PubMedCrossRef
108.
Yugawa, T., Narisawa-Saito, M., Yoshimatsu, Y., Haga, K., Ohno, S., Egawa, N., et al. (2010). DeltaNp63alpha repression of the Notch1 gene supports the proliferative capacity of normal human keratinocytes and cervical cancer cells. Cancer Research, 70(10), 4034–4044.PubMedCrossRef
109.
Dotto, G. P. (2009). Crosstalk of Notch with p53 and p63 in cancer growth control. Nature Reviews. Cancer, 8, 587–595.CrossRef
110.
Schwamborn, J. C., Berezikov, E., & Knoblich, J. A. (2009). The TRIM-NHL protein TRIM32 activates miRNAs and prevents self-renewal in mouse neural progenitors. Cell, 136(5), 913–925.PubMedCrossRef
111.
Loedige, I., & Filipowicz, W. (2009). TRIM-NHL proteins take on miRNA regulation. Cell, 136(5), 818–820.PubMedCrossRef
112.
113.
Boominathan, L. (2010). The tumor suppressors p53, p63 and p73 are regulators of miRNA processing complex. PLoS ONE, 5(5), e10615.PubMedCrossRef
114.
Viganò, M. A., Lamartine, J., Testoni, B., Merico, D., Alotto, D., Castagnoli, C., et al. (2006). New p63 targets in keratinocytes identified by a genome-wide approach. The EMBO Journal, 25(21), 5105–5116.PubMedCrossRef
115.
Lee, M., & Vasioukhin, V. (2008). Cell polarity and cancer–cell and tissue polarity as a non-canonical tumor suppressor. Journal of Cell Science, 121(Pt 8), 1141–1150.PubMedCrossRef
116.
Wodarz, A., & Gonzalez, C. (2006). Connecting cancer to the asymmetric division of stem cells. Cell, 124(6), 1121–1123.PubMedCrossRef
117.
118.
Tarasov, V., Jung, P., Verdoodt, B., Lodygin, D., Epanchintsev, A., et al. (2007). Differential regulation of miRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle, 6(13), 1586–1593.PubMedCrossRef
119.
Rosenbluth, J. M., Mays, D. J., Pino, M. F., Tang, L. J., & Pietenpol, J. A. (2008). A gene signature-based approach identifies mTOR as a regulator of p73. Molecular and Cellular Biology, 19, 5951–5964.CrossRef
120.
Kumar, M. S., Erkeland, S. J., Pester, R. E., Chen, C. Y., Ebert, M. S., Sharp, P. A., et al. (2008). Suppression of non-small cell lung tumor development by the let-7 miRNA family. Proceedings of the National Academy of Sciences of the United States of America, 105(10), 3903–3908.PubMedCrossRef
121.
Esquela-Kerscher, A., Trang, P., Wiggins, J. F., Patrawala, L., Cheng, A., Ford, L., et al. (2008). The let-7 miRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle, 7(6), 759–764.PubMedCrossRef
122.
Takamizawa, J., Konishi, H., Yanagisawa, K., Tomida, S., Osada, H., Endoh, H., et al. (2004). Reduced expression of the let-7 miRNAs in human lung cancers in association with shortened postoperative surviva. Cancer Research, 64(11), 3753–3756.PubMedCrossRef
123.
Johnson, C. D., Esquela-Kerscher, A., Stefani, G., Byrom, M., & Kelnar, K. (2007). The let-7 miRNA represses cell proliferation pathways in human cells. Cancer Research, 67(16), 7713–7722.PubMedCrossRef
124.
Baker, D. J., Perez-Terzic, C., Jin, F., Pitel, K., Niederländer, N. J., et al. (2008). Opposing roles for p16Ink4a and p19Arf in senescence and ageing caused by BubR1 insufficiency. Nature Cell Biology, 10(7), 825–836.PubMedCrossRef
125.
Bearzatto, A., Conte, D., Frattini, M., Zaffaroni, N., Andriani, F., et al. (2002). p16(INK4A) Hypermethylation detected by fluorescent methylation-specific PCR in plasmas from non-small cell lung cancer. Clinical Cancer Research, 8(12), 3782–3787.PubMed
126.
Seike, M., Gemma, A., Hosoya, Y., Hemmi, S., Taniguchi, Y., et al. (2000). Increase in the frequency of p16INK4 gene inactivation by hypermethylation in lung cancer during the process of metastasis and its relation to the status of p53. Clinical Cancer Research, 6(11), 4307–4313.PubMed
127.
Lee, H. (2003). Impaired phosphorylation and mis-localization of Bub1 and BubR1 are responsible for the defective mitotic checkpoint function in Brca2-mutant thymic lymphomas. Experimental & Molecular Medicine, 35(5), 448–453.
128.
Mullighan, C. G., Goorha, S., Radtke, I., Miller, C. B., Coustan-Smith, E., Dalton, J. D., et al. (2007). Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature, 446(7137), 758–764.PubMedCrossRef
129.
Yang, A., Zhu, Z., Kapranov, P., McKeon, F., Church, G. M., Gingeras, T. R., et al. (2006). Relationships between p63 binding, DNA sequence, transcription activity, and biological function in human cells. Molecular Cell, 24(4), 593–602.PubMedCrossRef
130.
Zhang, J., Jun Cho, S., & Chen, X. (2010). RNPC1, an RNA-binding protein and a target of the p53 family, regulates p63 expression through mRNA stability. Proceedings of the National Academy of Sciences of the United States of America, 107(21), 9614–9619.PubMedCrossRef
131.
132.
Lena, A. M., Shalom-Feuerstein, R., Rivetti di Val Cervo, P., Aberdam, D., Knight, R. A., Melino, G., et al. (2008). miR-203 represses ‘stemness’ by repressing DeltaNp63. Cell Death and Differentiation, 15(7), 1187–1195.PubMedCrossRef
133.
Lin, H. K., Chen, Z., Wang, G., Nardella, C., Lee, S. W., Chan, C. H., et al. (2010). Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature, 464(7287), 374–379.PubMedCrossRef
134.
Chan, C. H., Lee, S. W., Li, C. F., Wang, J., Yang, W. L., Wu, C. Y., et al. (2010). Deciphering the transcriptional complex critical for RhoA gene expression and cancer metastasis. Nature Cell Biology, 12(5), 457–467.PubMedCrossRef
135.
Zhang, S., Tang, Q., Xu, F., Xue, Y., Zhen, Z., Deng, Y., et al. (2009). RhoA regulates G1-S progression of gastric cancer cells by modulation of multiple INK4 family tumor suppressors. Molecular Cancer Research, 7(4), 570–580.PubMedCrossRef
136.
Tedesco, D., Lukas, J., & Reed, S. I. (2002). The pRb-related protein p130 is regulated by phosphorylation-dependent proteolysis via the protein-ubiquitin ligase SCF(Skp2). Genes & Development, 16(22), 2946–2957.CrossRef
137.
Kitagawa, M., Lee, S. H., & McCormick, F. (2008). Skp2 suppresses p53-dependent apoptosis by inhibiting p300. Molecular Cell, 29(2), 217–231.PubMedCrossRef
138.
Belletti, B., Nicoloso, M. S., Schiappacassi, M., Berton, S., Lovat, F., Wolf, K., et al. (2008). Stathmin activity influences sarcoma cell shape, motility, and metastatic potential. Molecular Biology of the Cell, 19(5), 2003–2013.PubMedCrossRef
139.
Keller, U. B., Old, J. B., Dorsey, F. C., Nilsson, J. A., Nilsson, L., MacLean, K. H., et al. (2007). Myc targets Cks1 to provoke the suppression of p27Kip1, proliferation and lymphomagenesis. The EMBO Journal, 26(10), 2562–2574.PubMedCrossRef
140.
Schaffer, B. E., Park, K. S., Yiu, G., Conklin, J. F., Lin, C., Burkhart, D. L., et al. (2010). Loss of p130 accelerates tumor development in a mouse model for human small-cell lung carcinoma. Cancer Research, 70(10), 3877–3883.PubMedCrossRef
141.
Gonzalez, S., Klatt, P., Delgado, S., Conde, E., Lopez-Rios, F., Sanchez-Cespedes, M., et al. (2006). Oncogenic activity of Cdc6 through repression of the INK4/ARF locus. Nature, 440(7084), 702–706.PubMedCrossRef
142.
Adorno, M., Cordenonsi, M., Montagner, M., Dupont, S., Wong, C., Hann, B., et al. (2009). A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell, 137(1), 87–98.PubMedCrossRef
143.
Viswanathan, S. R., Powers, J. T., Einhorn, W., Hoshida, Y., Ng, T., Toffanin, S., et al. (2009). Lin28 enhances tumorigenesis and is associated with advanced human malignancies. Nature Genetics, 41(7), 843–848.PubMedCrossRef
144.
Lee, Y. S., & Dutta, A. (2007). The tumor suppressor miRNA let-7 represses the HMGA2 oncogene. Genes & Development, 21(9), 1025–1030.CrossRef
145.
Nishino, J., Kim, I., Chada, K., & Morrison, S. J. (2008). Hmga2 promotes neural stem cell self-renewal in young but not old mice by reducing p16Ink4a and p19Arf Expression. Cell, 135(2), 227–239.PubMedCrossRef
146.
Thuault, S., Tan, E. J., Peinado, H., Cano, A., Heldin, C. H., & Moustakas, A. (2008). HMGA2 and Smads co-regulate SNAIL1 expression during induction of epithelial-to-mesenchymal transition. The Journal of Biological Chemistry, 283(48), 33437–33446.PubMedCrossRef
147.
Klanrit, P., Taebunpakul, P., Flinterman, M. B., Odell, E. W., Riaz, M. A., Melino, G., et al. (2009). PML involvement in the p73-mediated E1A-induced suppression of EGFR and induction of apoptosis in head and neck cancers. Oncogene, 28(39), 3499–3512.PubMedCrossRef
148.
Peter, M. E. (2009). Let-7 and miR-200 miRNAs: guardians against pluripotency and cancer progression. Cell Cycle, 8(6), 843–852.PubMed
149.
Boyerinas, B., Park, S. M., Shomron, N., Hedegaard, M. M., Vinther, J., Andersen, J. S., et al. (2008). Identification of let-7-regulated oncofetal genes. Cancer Research, 68(8), 2587–2591.PubMedCrossRef
150.
Yu, J., Vodyanik, M. A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J. L., Tian, S., et al. (2007). Induced pluripotent stem cell lines derived from human somatic cells. Science, 318(5858), 1917–1920.PubMedCrossRef
151.
Mao, H. J., Perez-losada, J., Wu, J., DelRosario, R., Tsunematsu, R., Nakayama, K. I., et al. (2004). Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene. Nature, 432, 775–779.PubMedCrossRef
152.
Sim, K. G., Zang, Z., Yang, C. M., Bonventre, J. V., & Hsu, S. I. (2004). TRIP-Br links E2F to novel functions in the regulation of cyclin E expression during cell cycle progression and in the maintenance of genomic stability. Cell Cycle, 3(10), 1296–1304.PubMed
153.
Welcker, W., Orian, A., Jin, J., Grim, J. A., Harper, J. W., Eisenman, R. N., et al. (2004). The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proceedings of the National Academy of Sciences of the United States of America, 101(24), 9085–9090.PubMedCrossRef
154.
Onoyama, I., Tsunematsu, R., Matsumoto, A., Kimura, T., de Alborán, I. M., Nakayama, K., et al. (2007). Conditional inactivation of Fbxw7 impairs cell-cycle exit during T cell differentiation and results in lymphomatogenesis. The Journal of Experimental Medicine, 204(12), 2875–2888.PubMedCrossRef
155.
Matsuoka, S., Oike, Y., Onoyama, I., Iwama, A., Arai, F., & Takubo, K. (2008). Fbxw7 acts as a critical fail-safe against premature loss of hematopoietic stem cells and development of T-ALL. Genes & Development, 22(8), 986–991.CrossRef
156.
Sachdeva, M., Zhu, S., Wu, F., Wu, H., Walia, V., Kumar, S., et al. (2009). p53 represses c-Myc through induction of the tumor suppressor miR-145. Proceedings of the National Academy of Sciences of the United States of America, 106(9), 3207–3212.PubMedCrossRef
157.
Liu, X., Sempere, L. F., Galimberti, F., Freemantle, S. J., Black, C., Dragnev, K. H., et al. (2009). Uncovering growth-suppressive MiRNAs in lung cancer. Clinical Cancer Research, 15(4), 1177–1183.PubMedCrossRef
158.
Yamasaki, L., Jacks, T., Bronson, R., Goillot, E., Harlow, E., & Dyson, N. J. (1996). Tumor induction and tissue atrophy in mice lacking E2F-1. Cell, 85(4), 537–548.PubMedCrossRef
159.
Chang, T. C., Zeitels, L. R., Hwang, H. W., Chivukula, R. R., Wentzel, E. A., Dews, M., et al. (2009). Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation. Proceedings of the National Academy of Sciences of the United States of America, 106(9), 3384–3389.PubMedCrossRef
160.
He, L., Thomson, J. M., Hemann, M. T., Hernando-Monge, E., Mu, D., Goodson, S., et al. (2005). A miRNA polycistron as a potential human oncogene. Nature, 435(7043), 828–833.PubMedCrossRef
161.
Ernst, A., Campos, B., Meier, J., Devens, F., Liesenberg, F., Wolter, M., et al. (2010). De-repression of CTGF via the miR-17-92 cluster upon differentiation of human glioblastoma spheroid cultures. Oncogene, 29(23), 3411–3422.PubMedCrossRef
162.
Mendell, J. T. (2008). miRiad roles for the miR-17-92 cluster in development and disease. Cell, 133(2), 217–222. Review.PubMedCrossRef
163.
Alimonti, A., Nardella, C., Chen, Z., Clohessy, J. G., Carracedo, A., Trotman, L. C., et al. (2010). A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis. The Journal of Clinical Investigation, 120(3), 681–693.PubMedCrossRef
164.
Matsubara, H., Takeuchi, T., Nishikawa, E., Yanagisawa, K., Hayashita, Y., Ebi, H., et al. (2007). Apoptosis induction by antisense oligonucleotides against miR-17-5p and miR-20a in lung cancers overexpressing miR-17–92. Oncogene, 26(41), 6099–6105.PubMedCrossRef
165.
Morris, E. J., Ji, J. Y., Yang, F., Di Stefano, L., Herr, A., Moon, N. S., et al. (2008). E2F1 represses beta-catenin transcription and is antagonized by both pRB and CDK8. Nature, 455(7212), 552–556.PubMedCrossRef
166.
Zhao, C., Blum, J., Chen, A., Kwon, H. Y., Jung, S. H., Cook, J. M., et al. (2007). Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell, 6, 528–541.CrossRef
167.
Stuart, S. A., Minami, Y., & Wang, J. Y. (2009). The CML stem cell: evolution of the progenitor. Cell Cycle, 8(9), 1338–1343.PubMed
168.
Yan, H. L., Xue, G., Mei, Q., Wang, Y. Z., Ding, F. X., Liu, M. F., et al. (2009). Repression of the miR-17–92 cluster by p53 has an important function in hypoxia-induced apoptosis. The EMBO Journal, 28(18), 2719–2732.PubMedCrossRef
169.
Bueno, M. J., Gomez de Cedrón, M., Laresgoiti, U., Fernández-Piqueras, J., Zubiaga, A., & Malumbres, M. (2010). Multiple E2F-induced microRNAs prevent replicative stress in response to mitogenic signalling. Molecular and Cellular Biology, 12, 2983–2995.CrossRef
170.
Mu, P., Han, Y. C., Betel, D., Yao, E., Squatrito, M., Ogrodowski, P., et al. (2009). Genetic dissection of the miR-17 92 cluster of microRNAs in Myc-induced B-cell lymphomas. Genes & Development, 23(24), 2806–2811.CrossRef
171.
Rempel, R. E., Mori, S., Gasparetto, M., Glozak, M. A., Andrechek, E. R., Adler, S. B., et al. (2009). A role for E2F activities in determining the fate of Myc-induced lymphomagenesis. PLoS Genetics, 5(9), e1000640.PubMedCrossRef
172.
Chang, T. C., Yu, D., Lee, Y. S., Wentzel, E. A., Arking, D. E., West, K. M., et al. (2008). Widespread miRNA repression by Myc contributes to tumorigenesis. Nature Genetics, 40(1), 43–50.PubMedCrossRef
173.
Gao, P., Tchernyshyov, I., Chang, T. C., Lee, Y. S., Kita, K., Ochi, T., et al. (2009). c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature, 458(7239), 762–765.PubMedCrossRef
174.
Watanabe, K., Ozaki, T., Nakagawa, T., Miyazaki, K., Takahashi, M., et al. (2002). Physical interaction of p73 with c-Myc and MM1, a c-Myc-binding protein, and modulation of the p73 function. The Journal of Biological Chemistry, 277(17), 15113–15123.PubMedCrossRef
175.
Horvilleur, E., Bauer, M., Goldschneider, D., Mergui, X., de la Motte, A., et al. (2008). p73alpha isoforms drive opposite transcriptional and post-transcriptional regulation of MYCN expression in neuroblastoma cells. Nucleic Acids Research, 36(13), 4222–4232.PubMedCrossRef
176.
Giuriato, S., Ryeom, S., Fan, A. C., Bachireddy, P., Lynch, R. C., Rioth, M. J., et al. (2006). Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch. Proceedings of the National Academy of Sciences of the United States of America, 103(44), 16266–16271.PubMedCrossRef
177.
Fabbri, M., Garzon, R., Cimmino, A., Liu, Z., Zanesi, N., Callegari, E., et al. (2007). MiRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proceedings of the National Academy of Sciences of the United States of America, 104(40), 15805–15810.PubMedCrossRef
178.
Garzon, R., Liu, S., Fabbri, M., Liu, Z., Heaphy, C. E., Callegari, E., et al. (2009). MiRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood, 113(25), 6411–6418.PubMedCrossRef
179.
Deneault, E., Cellot, S., Laverdure, F. A., JP, F. M., Chagraoui, J., et al. (2009). Functional screen to identify novel effectors of hematopoietic stem cell activity. Cell, 137(2), 369–379.PubMedCrossRef
180.
Wang, H., Garzon, R., Sun, H., Ladner, K. J., Singh, R., Dahlman, J., et al. (2008). NF-kappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma. Cancer Cell, 14(5), 369–381.PubMedCrossRef
181.
Park, Y., Lee, J. H., Ha, M., Nam, J. W., & Kim, V. N. (2009). miR-29 miRNAs activate p53 by targeting p85 alpha and CDC42. Nature Structural & Molecular Biology, 16(1), 23–29.CrossRef
182.
Sinha, A. U., Kaimal, V., Chen, J., & Jegga, A. G. (2008). Dissecting microregulation of a master regulatory network. BMC Genomics, 9, 88.PubMedCrossRef
183.
Lujambio, A., Calin, G. A., Villanueva, A., Ropero, S., Sánchez-Céspedes, M., Blanco, D., et al. (2008). A miRNA DNA methylation signature for human cancer metastasis. Proceedings of the National Academy of Sciences of the United States of America, 105(36), 13556–13561.PubMedCrossRef
184.
Duursma, A. M., Kedde, M., Schrier, M., le Sage, C., & Agami, R. (2008). miR-148 targets human DNMT3b protein coding region. RNA, 14(5), 872–877.PubMedCrossRef
185.
Kato, M., Zhang, J., Wang, M., Lanting, L., Yuan, H., Rossi, J. J., et al. (2007). MiRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors. Proceedings of the National Academy of Sciences of the United States of America, 104(9), 3432–3437.PubMedCrossRef
186.
Braun, C. J., Zhang, X., Savelyeva, I., Wolff, S., Moll, U. M., Schepeler, T., et al. (2008). p53-Responsive miRNAs 192 and 215 are capable of inducing cell cycle arrest. Cancer Research, 68(24), 1094–1104.CrossRef
187.
Georges, S. A., Biery, M. C., Kim, S. Y., Schelter, J. M., Guo, J., Chang, A. N., et al. (2008). Coordinated regulation of cell cycle transcripts by p53-Inducible miRNAs, miR-192 and miR-215. Cancer Research, 68(24), 10105–10112.PubMedCrossRef
188.
Gregory, P. A., Bert, A. G., Paterson, E. L., Barry, S. C., Tsykin, A., Farshid, G., et al. (2008). The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nature Cell Biology, 10(5), 593–601.PubMedCrossRef
189.
Bracken, C. P., Gregory, P. A., Kolesnikoff, N., Bert, A. G., Wang, J., Shannon, M. F., et al. (2008). A double-negative feedback loop between ZEB1-SIP1 and the miRNA-200 family regulates epithelial-mesenchymal transition. Cancer Research, 68(19), 7846–7854.PubMedCrossRef
190.
Gebeshuber, C. A., Zatloukal, K., & Martinez, J. (2009). miR-29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis. EMBO Reports, 10(4), 400–405.PubMedCrossRef
191.
Sengupta, S., den Boon, J. A., Chen, I. H., Newton, M. A., Stanhope, S. A., Cheng, Y. J., et al. (2008). MiRNA 29c is down-regulated in nasopharyngeal carcinomas, up-regulating mRNAs encoding extracellular matrix proteins. Proceedings of the National Academy of Sciences of the United States of America, 105(15), 5874–5878.PubMedCrossRef
192.
Qin, L., Liao, L., Redmond, A., Young, L., Yuan, Y., Chen, H., et al. (2008). The AIB1 oncogene promotes breast cancer metastasis by activation of PEA3-mediated matrix metalloproteinase 2 (MMP2) and MMP9 expression. Molecular and Cellular Biology, 19, 5937–5950.CrossRef
193.
Zenz, T., Mohr, J., Eldering, E., Kater, A. P., Buhler, A., Kienle, D., et al. (2009). MiR-34a as part of the resistance network in chronic lymphocytic leukemia. Blood, 113(16), 3801–3808.PubMedCrossRef
194.
He, L., He, X., Lim, L. P., de Stanchina, E., Xuan, Z., Liang, Y., et al. (2007). miRNA component of the p53 tumour suppressor network. Nature, 447(7148), 1130–1134.PubMedCrossRef
195.
He, L., He, X., Lowe, S. W., & Hannon, G. J. (2007). miRNAs join the p53 network—another piece in the tumour-suppression puzzle. Nature Reviews. Cancer, 7(11), 819–822. Review.PubMedCrossRef
196.
Sun, F., Fu, H., Liu, Q., Tie, Y., Zhu, J., Xing, R., et al. (2008). Downregulation of CCND1 and CDK6 by miR-34a induces cell cycle arrest. FEBS Letters, 582(10), 1564–1568.PubMedCrossRef
197.
Aslanian, A., Iaquinta, P. J., Verona, R., & Lees, J. A. (2004). Repression of the Arf tumor suppressor by E2F3 is required for normal cell cycle kinetics. Genes & Development, 18(12), 1413–1422.CrossRef
198.
Ji, Q., Hao, X., Meng, Y., Zhang, M., Desano, J., Fan, D., et al. (2008). Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC Cancer, 8, 266.PubMedCrossRef
199.
Wang, S., Yuan, Y., Liao, L., Kuang, S. Q., Tien, J. C., O’Malley, B. W., et al. (2009). Disruption of the SRC-1 gene in mice suppresses breast cancer metastasis without affecting primary tumor formation. Proceedings of the National Academy of Sciences of the United States of America, 106(1), 151–156.PubMedCrossRef
200.
Qin, L., Liu, Z., Chen, H., & Xu, J. (2009). The steroid receptor coactivator-1 regulates twist expression and promotes breast cancer metastasis. Cancer Research, 69(9), 3819–3827.PubMedCrossRef
201.
Nguyen, D. X., Chiang, A. C., Zhang, X. H., Kim, J. Y., Kris, M. G., Ladanyi, M., et al. (2009). WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell, 138(1), 51–62.PubMedCrossRef
202.
Bonci, D., Coppola, V., Musumeci, M., Addario, A., Giuffrida, R., Memeo, L., et al. (2008). The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Natural Medicines, 14(11), 1271–1277.CrossRef
203.
Klein, U., Lia, M., Crespo, M., Siegel, R., Shen, Q., Mo, T., et al. (2010). The DLEU2/miR-15a/16–1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell, 17(1), 28–40.PubMedCrossRef
204.
Cimmino, A., Calin, G. A., Fabbri, M., Iorio, M. V., Ferracin, M., Shimizu, M., et al. (2005). miR-15 and miR-16 induce apoptosis by targeting BCL2. Proceedings of the National Academy of Sciences of the United States of America, 102(39), 13944–13949.PubMedCrossRef
205.
Calin, G. A., Cimmino, A., Fabbri, M., Ferracin, M., Wojcik, S. E., Shimizu, M., et al. (2008). MiR-15a and miR-16-1 cluster functions in human leukemia. Proceedings of the National Academy of Sciences of the United States of America, 105(13), 5166–5171.PubMedCrossRef
206.
Chatterjee, A., Chang, X., Sen, T., Ravi, R., Bedi, A., & Sidransky, D. (2010). Regulation of p53 family member isoform DeltaNp63alpha by the nuclear factor-kappaB targeting kinase IkappaB kinase beta. Cancer Research, 70(4), 1419–1429.PubMedCrossRef
207.
208.
Dovey, J. S., Zacharek, S. J., Kim, C. F., & Lees, J. A. (2008). Bmi1 is critical for lung tumorigenesis and bronchioalveolar stem cell expansion. Proceedings of the National Academy of Sciences of the United States of America, 105(33), 11857–11862.PubMedCrossRef
209.
Bueno, M. J., Gómez de Cedrón, M., Laresgoiti, U., Fernández-Piqueras, J., Zubiaga, A. M., & Malumbres, M. (2010). Multiple E2F-induced microRNAs prevent replicative stress in response to mitogenic signaling. Molecular and Cellular Biology, 30(12), 2983–2995.PubMedCrossRef
210.
Sander, S., Bullinger, L., Klapproth, K., Fiedler, K., Kestler, H. A., Barth, T. F., et al. (2008). MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. Blood, 112(10), 4202–4212.PubMedCrossRef
211.
Sander, S., Bullinger, L., & Wirth, T. (2009). Repressing the repressor: a new mode of MYC action in lymphomagenesis. Cell Cycle, 8(4), 556–559.PubMed
212.
Fujii, S., & Ochiai, A. (2008). Enhancer of zeste homolog 2 downregulates E-cadherin by mediating histone H3 methylation in gastric cancer cells. Cancer Science, 99(4), 738–746.PubMedCrossRef
213.
Fujii, S., Ito, K., Ito, Y., & Ochiai, A. (2008). Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation. The Journal of Biological Chemistry, 283(25), 17324–17332.PubMedCrossRef
214.
Cao, Q., Yu, J., Dhanasekaran, S. M., Kim, J. H., Mani, R. S., Tomlins, S. A., et al. (2008). Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene, 27(58), 7274–7284.PubMedCrossRef
215.
Beke, L., Nuytten, M., Van Eynde, A., Beullens, M., & Bollen, M. (2007). The gene encoding the prostatic tumor suppressor PSP94 is a target for repression by the Polycomb group protein EZH2. Oncogene, 26(31), 4590–4595.PubMedCrossRef
216.
Yang, X., Karuturi, R. K., Sun, F., Aau, M., Yu, K., Shao, R., et al. (2009). CDKN1C (p57) is a direct target of EZH2 and suppressed by multiple epigenetic mechanisms in breast cancer cells. PLoS ONE, 4(4), e5011.PubMedCrossRef
217.
Ezhkova, E., Pasolli, H. A., Parker, J. S., Stokes, N., Su, I. H., Hannon, G., et al. (2009). Ezh2 orchestrates gene expression for the stepwise differentiation of tissue-specific stem cells. Cell, 136(6), 1122–1135.PubMedCrossRef
218.
Kota, J., Chivukula, R. R., O’Donnell, K. A., Wentzel, E. A., Montgomery, C. L., et al. (2009). Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell, 137(6), 1005–1017.PubMedCrossRef
219.
Friedman, J. M., Liang, G., Liu, C. C., Wolff, E. M., Tsai, Y. C., et al. (2009). The putative tumor suppressor miRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2. Cancer Research, 69(6), 2623–2629.PubMedCrossRef
220.
Faber, J., Krivtsov, A. V., Stubbs, M. C., Wright, R., Davis, T. N., van den Heuvel-Eibrink, M., et al. (2009). HOXA9 is required for survival in human MLL-rearranged acute leukemias. Blood, 113(11), 2375–2385.PubMedCrossRef
221.
Rowland, B. D., Bernards, R., & Peeper, D. S. (2005). The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene. Nature Cell Biology, 7(11), 1074–1082.PubMedCrossRef
222.
Li, Y., Zhou, Z., & Chen, C. (2008). WW domain-containing E3 ubiquitin protein ligase 1 targets p63 transcription factor for ubiquitin-mediated proteasomal degradation and regulates apoptosis. Cell Death and Differentiation, 15(12), 1941–1951.PubMedCrossRef
223.
Yu, F., Deng, H., Yao, H., Liu, Q., Su, F., Song, E. (2010) Mir-30 reduction maintains self-renewal and inhibits apoptosis in breast tumor-initiating cells. Oncogene (in press)
224.
Braun, J., Hoang-Vu, C., Dralle, H., Hüttelmaier, S. (2010) Downregulation of microRNAs directs the EMT and invasive potential of anaplastic thyroid carcinomas. Oncogene (in press)
225.
Chang, T. C., Wentzel, E. A., Kent, O. A., Ramachandran, K., Mullendore, M., Lee, K. H., et al. (2007). Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Molecular Cell, 26(5), 745–752.PubMedCrossRef
226.
Kim, W. Y., Perera, S., Zhou, B., Carretero, J., Yeh, J. J., Heathcote, S. A., et al. (2009). HIF2alpha cooperates with RAS to promote lung tumorigenesis in mice. The Journal of Clinical Investigation, 119(8), 2160–2170.PubMedCrossRef
227.
Li, Z., Bao, S., Wu, Q., Wang, H., Eyler, C., Sathornsumetee, S., et al. (2009). Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell, 15(6), 501–513.PubMedCrossRef
228.
Keith, B., & Simon, M. C. (2007). Hypoxia-inducible factors, stem cells, and cancer. Cell, 129(3), 465–472. Review.PubMedCrossRef
229.
Gordan, J. D., & Simon, M. C. (2007). Hypoxia-inducible factors: central regulators of the tumor phenotype. Current Opinion in Genetics & Development, 17(1), 71–77. Review.CrossRef
230.
Gort, E. H., Groot, A. J., van der Wall, E., van Diest, P. J., & Vooijs, M. A. (2008). Hypoxic regulation of metastasis via hypoxia-inducible factors. Current Molecular Medicine, 8(1), 60–67. Review.PubMedCrossRef
231.
Jazdzewski, K., Murray, E. L., Franssila, K., Jarzab, B., Schoenberg, D. R., & de la Chapelle, A. (2008). Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 105(20), 7269–7274.PubMedCrossRef
232.
Jazdzewski, K., Liyanarachchi, S., Swierniak, M., Pachucki, J., Ringel, M. D., Jarzab, B., et al. (2009). Polymorphic mature miRNAs from passenger strand of pre-miR-146a contribute to thyroid cancer. Proceedings of the National Academy of Sciences of the United States of America, 106(5), 1502–1505.PubMedCrossRef
233.
Lin, S. L., Chiang, A., Chang, D., & Ying, S. Y. (2008). Loss of mir-146a function in hormone-refractory prostate cancer. RNA, 14(3), 417–424.PubMedCrossRef
234.
Hurst, D. R., Edmonds, M. D., Scott, G. K., Benz, C. C., Vaidya, K. S., & Welch, D. R. (2009). Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis. Cancer Research, 69(4), 1279–1283.PubMedCrossRef
235.
Onder, T. T., Gupta, P. B., Mani, S. A., Yang, J., Lander, E. S., & Weinberg, R. A. (2008). Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Research, 68(10), 3645–3654.PubMedCrossRef
236.
Mani, S. A., Guo, W., Liao, M. J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., et al. (2008). The epithelial–mesenchymal transition generates cells with properties of stem cells. Cell, 133(4), 704–715.PubMedCrossRef
237.
Khew-Goodall, Y., & Goodall, G. J. (2010). Myc-modulated miR-9 makes more metastases. Nature Cell Biology, 12(3), 209–211.PubMed
238.
Ma, L., Young, J., Prabhala, H., Pan, E., Mestdagh, P., Muth, D., et al. (2010). miR-9, a MYC/MYCN-activated miRNA, regulates E-cadherin and cancer metastasis. Nature Cell Biology, 12(3), 247–256.PubMed
239.
Smith, S. C., & Theodorescu, D. (2009). Learning therapeutic lessons from metastasis suppressor proteins. Nature Reviews. Cancer, 9(4), 253–264.PubMedCrossRef
240.
Kim, J. W., Mori, S., & Nevins, J. R. (2010). Myc-induced MicroRNAs integrate Myc-mediated cell proliferation and cell fate. Cancer Research, 70(12), 4820–4828.PubMedCrossRef
241.
Garofalo, M., Di Leva, G., Romano, G., Nuovo, G., Suh, S. S., Ngankeu, A., et al. (2009). miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell, 16(6), 498–509.PubMedCrossRef
242.
Fornari, F., Gramantieri, L., Ferracin, M., Veronese, A., Sabbioni, S., Calin, G. A., et al. (2008). MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene, 27(43), 5651–5661.PubMedCrossRef
243.
Wu, C. H., van Riggelen, J., Yetil, A., Fan, A. C., Bachireddy, P., & Felsher, D. W. (2007). Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. Proceedings of the National Academy of Sciences of the United States of America, 104(32), 13028–13033.PubMedCrossRef
244.
Guney, I., Wu, S., & Sedivy, J. M. (2006). Reduced c-Myc signaling triggers telomere independent senescence by regulating Bmi-1 and p16(INK4a). Proceedings of the National Academy of Sciences of the United States of America, 103(10), 3645–3650.PubMedCrossRef
245.
Nemajerova, A., Petrenko, O., Trümper, L., Palacios, G., & Moll, U. M. (2010). Loss of p73 promotes dissemination of Myc-induced B cell lymphomas in mice. The Journal of Clinical Investigation, 120(6), 2070–2080.PubMedCrossRef
246.
Zheng, H., Ying, H., Yan, H., Kimmelman, A. C., Hiller, D. J., Chen, A. J., et al. (2008). p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature, 455(7216), 1129–1133.PubMedCrossRef
247.
Liu, X., Karnell, JL., Yin, B., Zhang, R., Zhang, J., Li, P., et al. (2010) Distinct roles for PTEN in prevention of T cell lymphoma and autoimmunity in mice. J Clin Invest (in press)
248.
Guo, W., Lasky, J. L., Chang, C. J., Mosessian, S., Lewis, X., Xiao, Y., et al. (2008). Multi-genetic events collaboratively contribute to Pten-null leukaemia stem-cell formation. Nature, 453(7194), 529–533.PubMedCrossRef
249.
Yanagi, S., Kishimoto, H., Kawahara, K., Sasaki, T., Sasaki, M., Nishio, M., et al. (2007). Pten controls lung morphogenesis, bronchioalveolar stem cells, and onset of lung adenocarcinomas in mice. The Journal of Clinical Investigation, 117(10), 2929–2940.PubMedCrossRef
250.
Du, L., & Pertsemlidis, A. (2010). microRNAs and lung cancer: tumors and 22-mers. Cancer and Metastasis Reviews, 29(1), 109–122. Review.PubMedCrossRef
251.
Gregory, M. A., Qi, Y., & Hann, S. R. (2005). The ARF tumor suppressor: keeping Myc on a leash. Cell Cycle, 4(2), 24952.
252.
Nicholson, S. A., Okby, N. T., Khan, M. A., Welsh, J. A., McMenamin, M. G., Travis, W. D., et al. (2001). Alterations of p14ARF, p53, and p73 genes involved in the E2F-1-mediated apoptotic pathways in non-small cell lung carcinoma. Cancer Research, 61(14), 5636–5643.PubMed
253.
Inoue, K., Mallakin, A., & Frazier, D. P. (2007). Dmp1 and tumor suppression. Oncogene, 26(30), 4329–4335. Review.PubMedCrossRef
254.
Mallakin, A., Sugiyama, T., Taneja, P., Matise, L. A., Frazier, D. P., Choudhary, M., et al. (2007). Mutually exclusive inactivation of DMP1 and ARF/p53 in lung cancer. Cancer Cell, 12(4), 381–394.PubMedCrossRef
255.
Inoue, K., Sugiyama, T., Taneja, P., Morgan, R. L., & Frazier, D. P. (2008). Emerging roles of DMP1 in lung cancer. Cancer Research, 68(12), 4487–4490. Review.PubMedCrossRef
256.
257.
Xi, Y., Shalgi, R., Fodstad, O., Pilpel, Y., & Ju, J. (2006). Differentially regulated micro-RNAs and actively translated messenger RNA transcripts by tumor suppressor p53 in colon cancer. Clinical Cancer Research, 12(7 Pt 1), 2014–2024.PubMedCrossRef
258.
Theurkauf, W. E., Klattenhoff, C., Bratu, D. P., McGinnis-Schultz, N., Koppetsch, B. S., & Cook, H. A. (2006). rasiRNAs, DNA damage, and embryonic axis specification. Cold Spring Harbor Symposia on Quantitative Biology, 71, 171–180.PubMedCrossRef
259.
Kutter, C., & Svoboda, P. (2008). miRNA, siRNA, piRNA: knowns of the unknown. RNA Biology, 5(4), 181–188.PubMed
260.
Metadata
Title
The guardians of the genome (p53, TA-p73, and TA-p63) are regulators of tumor suppressor miRNAs network
Author
Lakshmanane Boominathan
Publication date
01-12-2010
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 4/2010
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-010-9257-9

Other articles of this Issue 4/2010

Cancer and Metastasis Reviews 4/2010 Go to the issue

NON-THEMATIC REVIEW

DNA methylation or histone modification status in metastasis and angiogenesis-related genes: a new hypothesis on usage of DNMT inhibitors and S-adenosylmethionine for genome stability

NON-THEMATIC REVIEW

Feedback regulation of proteasome gene expression and its implications in cancer therapy

NON-THEMATIC REVIEW

DNA repair pathways and their implication in cancer treatment

NON-THEMATIC REVIEW

Obesity and breast cancer: status of leptin and adiponectin in pathological processes

NON-THEMATIC REVIEW

Perspectives on the mesenchymal origin of metastatic cancer

NON-THEMATIC REVIEW

Distant metastases do not metastasize
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits